NICE to review guidance on Servier's Protelos after legal challenge
This article was originally published in Scrip
The health technology appraisal body for England and Wales, NICE, will have to review its guidance on Servier's Protelos (strontium ranelate) for preventing osteoporotic fragility fractures, said a UK judge last week. Moreover, NICE must be clear in its reasoning when it reaches a different conclusion from that of "eminent bodies" such as the European Medicines Agency (EMA), according to the judgement.
You may also be interested in...
The R&D-based lobby group, Medicines Australia, has published a report calling for stakeholders across the Australian healthcare ecosystem to discuss how to “pragmatically address the evidence needs of the future.”
NICE will review new data in deciding whether to ok the use of Spinraza in non-ambulant SMA type III patients.
WTO member states including the EU, the US and the UK argue that waiving certain IP rights is unnecessary for enhancing responses to the Covid-19 pandemic.